Carcinogenesis Advance Access originally published online on March 2, 2006
Carcinogenesis 2006 27(7):1316-1322; doi:10.1093/carcin/bgi373
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Epigenetic alterations in RASSF1A in human aberrant crypt foci
1 Center for Molecular Medicine, 2 Colon Cancer Prevention Program, Neag Comprehensive Cancer Center, 3 Department of Pathology and 4 Division of Gastroenterology, UCHC School of Medicine, University of Connecticut Health Center, Farmington, CT, USA
* To whom correspondence should be addressed at: University of Connecticut Health Center, Center for Molecular Medicine, 263 Farmington Avenue, Farmington, CT 06030-3101. Tel: +860 679 8704; Fax: +860 679 7639; Email: Rosenberg{at}nso1.uchc.edu
CpG island methylation (CIM) is an epigenetic mechanism for transcriptional silencing that occurs at various stages of colon tumorigenesis. CIM has been found in serrated adenomas and hyperplastic polyps. There is also evidence for hypermethylation in aberrant crypt foci (ACF) that are found in resected colons from cancer patients. Our study addresses promoter methylation of a tumor suppressor gene, RASSF1A, within the colonic epithelium of subjects undergoing screening colonoscopies in the absence of synchronous tumors. Patients included in this study were at elevated risk for colorectal cancer (CRC) based on family history, but without a previously occurring or synchronous colon carcinoma. ACF were identified using close-focus magnifying chromendoscopy and collected by biopsy in situ. We isolated ACF and adjacent normal colonic epithelium by laser capture microdissection (LCM) and studied methylation of the RASSF1A promoter region in ACF and in adjacent normal mucosa. Expression of RASSF1A was verified using quantitative real-time polymerase chain reaction (QRTPCR). We found that 8.6% (3 out of 35) of ACF had K-ras mutations and 24% (6 out of 25) had RASSF1A hypermethylation. Our results demonstrate that RASSF1A hypermethylation and K-ras mutations are not mutually exclusive and are present in patients at elevated risk of CRC. Importantly, CIM of RASSF1A is an early epigenetic aberration, occurring in the absence of synchronous colon tumors and is not accompanied by field effects into the surrounding epithelium.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
D. Dietrich, R. Lesche, R. Tetzner, M. Krispin, J. Dietrich, W. Haedicke, M. Schuster, and G. Kristiansen Analysis of DNA Methylation of Multiple Genes in Microdissected Cells From Formalin-fixed and Paraffin-embedded Tissues J. Histochem. Cytochem., May 1, 2009; 57(5): 477 - 489. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D.F. Licchesi, W. H. Westra, C. M. Hooker, and J. G. Herman Promoter Hypermethylation of Hallmark Cancer Genes in Atypical Adenomatous Hyperplasia of the Lung Clin. Cancer Res., May 1, 2008; 14(9): 2570 - 2578. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ogino, A. Hazra, G. J. Tranah, G. J. Kirkner, T. Kawasaki, K. Nosho, M. Ohnishi, Y. Suemoto, J. A. Meyerhardt, D. J. Hunter, et al. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer Carcinogenesis, September 1, 2007; 28(9): 1985 - 1990. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Rosenberg, S. Yang, D. C. Pleau, E. J. Greenspan, R. G. Stevens, T. V. Rajan, C. D. Heinen, J. Levine, Y. Zhou, and M. J. O'Brien Mutations in BRAF and KRAS Differentially Distinguish Serrated versus Non-Serrated Hyperplastic Aberrant Crypt Foci in Humans Cancer Res., April 15, 2007; 67(8): 3551 - 3554. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Greenspan, J. L. Cyr, D. C. Pleau, J. Levine, T. V. Rajan, D. W. Rosenberg, and C. D. Heinen Microsatellite instability in aberrant crypt foci from patients without concurrent colon cancer Carcinogenesis, April 1, 2007; 28(4): 769 - 776. [Abstract] [Full Text] [PDF] |
||||



